WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Endocyte Inc., a clinical-stage company developing small-molecule guided drug technologies, announces that data from four clinical studies of the company's investigational compounds will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 4-8 in Chicago. With more than 28,000 members, ASCO is the world's leading professional organization representing medical oncologists.
